IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial

IN8bio (INAB) announced positive Phase 1 trial results for INB-200, a gamma-delta T cell therapy, in newly diagnosed glioblastoma (GBM). Patient 009, with an IDH-mutant glioma, achieved remission and has survived for four years post-treatment, significantly exceeding typical progression-free outcomes. Updated data presented at ASCO 2025 showed repeated INB-200 doses extended median progression-free survival (mPFS) to 16.1 months, more than double the 6.9 months observed with standard care, suggesting potential for INB-200 in treating this aggressive cancer.

Analysis

IN8bio, Inc. (Nasdaq: INAB) has reported a significant clinical milestone from its Phase 1 trial of INB-200, a gamma-delta T cell therapy, for newly-diagnosed glioblastoma (GBM). Specifically, Patient 009, diagnosed with a grade 4, IDH-mutant glioma, has achieved a 4-year remission and survival post-treatment with INB-200, an outcome that substantially surpasses progression-free outcomes typically observed. This individual patient success is complemented by updated Phase 1 data presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, which indicated that repeated doses of INB-200 extended median Progression-Free Survival (mPFS) to 16.1 months, more than doubling the 6.9 months generally seen with the standard-of-care Stupp protocol. INB-200, highlighted as the first genetically modified gamma-delta T cell therapy evaluated in GBM, has also demonstrated a favorable safety profile. These developments are particularly compelling as the standard of care for newly diagnosed GBM has not advanced overall survival beyond 14-16 months in over two decades, underscoring INB-200's potential to address a critical unmet medical need in this aggressive and difficult-to-treat cancer.

Key Decisions for Investors

• The reported 4-year remission for a patient and the extended median Progression-Free Survival of 16.1 months for INB-200 in Phase 1 are highly encouraging early signals that could significantly de-risk the asset and attract further attention to IN8bio's gamma-delta T cell platform.
• Investors should recognize that INB-200 is still in early-stage clinical development; successful translation of these Phase 1 results into larger, confirmatory Phase 2/3 trials and eventual regulatory approval remains a critical path with inherent biopharmaceutical development risks.
• Careful monitoring of upcoming clinical trial readouts for INB-200, progress in IN8bio's broader pipeline including INB-100 for AML and INB-400 for GBM, and any updates on regulatory interactions will be crucial, as these represent key potential value inflection points.
• Given the clinical-stage nature of IN8bio, any investment position should be carefully weighed against the high-risk, high-reward profile characteristic of biopharmaceutical companies heavily reliant on research and development success and subject to binary clinical outcomes.